Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellular Biomedicine Group (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, has announced it has completed the previously announced acquisition of privately held Agreen Biotech and its founder's US patent.
Subscribe to our email newsletter
AG’s IP is comprised of T Cells Receptor ("TCR") clonality analysis technology and T Central Memory Cell ("Tcm") and Dendritic Cell ("DC") preparation methodologies.
The TCR clonality analysis technology is based on the use of multiple sets of unique primers to amplify 22 regions of the TCR, thereby detecting clonal expansions related to antigen stimulation of the immune system, which enables the assessment of tumor specific immunity with high accuracy and efficiency.
Tcm cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity; and they are the key element of immunocellular fortification against tumors, infections and immune disorders.
"The acquisition of AG accelerates the Company’s strategy to grow its cancer immune cell therapy segment with a platform that presents the potential to complement or replace invasive chemotherapy for certain cancers. CBMG plans to expand AG’s business position and grow the cancer patient tumor specific immunity assessment revenue by servicing additional hospitals. We warmly welcome the integration of thirty talented staff from AG into the CBMG family. Their addition will enable CBMG to expand beyond its Shanghai and Wuxi operations in China into northern regions of the country," said Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.
Under the terms of the agreement, CBMG will pay a consideration of approximately $3.3 million in cash and the issuance of 822,522 shares of CBMG common stock, subject to a one-year lock-up period, from the date of the agreement, in exchange for all shares of AG and its founder’s U.S. patent.
Additional information can be found in the Form 8-K which will be filed by Cellular Biomedicine Group with the Securities and Exchange Commission on or before October 2, 2014.?